`Millions
`
`$500
`
`$450
`
`$400
`
`$350
`
`$300
`
`$250
`
`$200
`
`$150
`
`$100
`
`$50
`
`$0
`2007
`
`2008
`
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`2015
`
`2016
`
`2017
`
`2018
`
`e-♦-- Basaglar KwikPen
`
`.-.--. Lantus SoloST AR
`
`.--.---a Levemir Pens
`
`.-.--. Toujeo SoloSTAR
`
`.--.---a Tresiba FlexTouch
`
`Source: IMS Health
`Note: Marketing is the sum of PROMOTIONS DOLLARS EXC SAMPLES and SAMPLES DOLLARS. PROMOTIONS DOLLARS EXC SAMPLES data span June 2002 through October
`2018. SAMPLES DOLLARS data span January 2007 through October 2018. The long-acting category includes drugs listed under the IMS USC5 codes 39123 (Human Insulins Long
`Acting), 39133 (Analogs of Human Insulin Long Acting), and 39135 (Analogs of Human Insulin Ultra Long Acting). Marketing data are unavailable for Lantus OptiClik. Basaglar KwikPen
`consists of drugs I isted as "Basaglar" and "Basaglar Kwi kPen." Lantus SoloSTAR consists of the drug I isted as "Lantus SoloST AR." Levemir Pens consists of drugs listed as "Levem ir
`FlexPen" and "Levemir FlexTouch." Toujeo SoloSTAR consists of drugs listed as "Toujeo," "Toujeo SoloSTAR," and "Toujeo Max SoloSTAR." Tresiba FlexTouch consists of drugs
`listed as "Tresiba," "Insulin Degludec," and "Tresiba FlexTouch."
`
`Sanofi Exhibit 2204.001
`Mylan v. Sanofi
`IPR2018-01675
`
`